HURA TuHURA Biosciences, Inc.: Market Capitalization to Book Value Ratio
TuHURA Biosciences, Inc. (HURA) specializes in developing advanced oncology treatments. This price chart illustrates the asset's market dynamics, with its indicator currently at 7.09. The business relies on outsourcing drug production through CDMO partners in the US, while its growth strategy is based on implementing innovative vaccines and overcoming drug resistance with the support of major investors.
%20Market%20Cap%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_HURA_-_TuHURA-Biosciences-Inc._-_Market-Cap-to-Net-Assets-Ratio "TuHURA Biosciences, Inc. (HURA) Market Capitalization to Book Value Ratio: for the period 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company TuHURA Biosciences, Inc. (HURA)
- share price and expert price forecast:
- company stock capitalization data:
- balance sheet net asset value indicators:
- debt and liquidity details:
Total Debt to Capital TuHURA Biosciences, Inc.|HURA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital tuhurabio.com|HURA - Company Cumulative Debt|Debt to Book Capitalization Ratio TuHURA|HURA - Company Long-Term Loans and Borrowings|Company Current Liabilities TuHURA Biosciences|Quick Ratio tuhurabio.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:TuHURA Biosciences, Inc.
This indicator compares the current market value of shares with the company's net assets, determining the extent of the premium or discount of the quotes relative to real capital. For TuHURA Biosciences, Inc. (HURA), which relies on external funding for early clinical trials, the ratio of market value to book capital serves as a critical marker of speculative asset overvaluation against a backdrop of high liquidity gap risk.
Who TuHURA Biosciences, Inc. competes with
ONC: Market Capitalization to Book Value Ratio|halozyme.com (HALO) - Market Capitalization to Book Value Ratio|RVMD (Revolution Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Ascentage Pharma Group International (AAPG)|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio UroGen Pharma Corp (URGN)|Market Value to Book Value Ratio Bicara Therapeutics Inc. BCAX|PSNL: Capitalization to Book Value Ratio|Erasca - Market Capitalization to Book Value Ratio|Delcath Systems Inc (DCTH) - Market Cap to Net Assets Ratio|YMAB: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Aura Corp (AURA)|Market Value to Book Value Ratio Candel Therapeutics Inc.|ARAY: Market Value to Book Value|Market Cap to Net Assets Ratio SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio CTOR (Citius Oncology, Inc)|TARA - Market Cap to Net Assets Ratio|FATE: Market Cap to Net Assets Ratio|WHWK - Market Capitalization to Book Value Ratio|tscan.com (TCRX) - Market Value to Book Value Ratio|Champions Oncology, Inc. - Market Value to Book Value|XBIT (XBiotech Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CEL-SCI Corp CVM|Market Cap to Net Assets Ratio OSTX (OS Therapies Incorporated)|Market Cap to Book Value Multiple RADX|Artiva Biotherapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Adlai Nortye Ltd ANL|Veru Pharma - Market Capitalization to Book Value Ratio|Market Value to Book Value TPST (Tempest Therapeutics Corp)|XLO (xiliotx.com) - Market Cap to Net Assets Ratio|Renovaro (RENB) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Mural Oncology PLC|KAPA: Market Value to Book Value|Market Capitalization to Book Value Ratio OKUR|Market Capitalization to Book Value Ratio w2.cytomed.sg (GDTC)|Curis - Market Cap to Net Assets Ratio|Market Value to Book Value APLM|Tharimmune - Market Capitalization to Book Value Ratio|ADVB: Market Value to Book Value Ratio|GNPX: Market Capitalization to Book Value Ratio|CLDI - Market Capitalization to Book Value|Market Value to Book Value Ratio Sunshine Biopharma|Market-to-Book Ratio Xenetic Bio XBIO|Market Value to Book Value Ratio Salarius Pharmaceuticals, Inc. (SLRX)|Market Capitalization to Book Value Purple Biotech Ltd|Market Capitalization to Book Value Ratio AONC (American Oncology Network, Inc.)|BGNE - Market Cap to Net Assets Ratio|Checkpoint Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Elevation Oncology Inc. ELEV|ICAD: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Ikena Oncology (IKNA)|Market Value to Book Value Ratio Notable Labs Inc.|Capitalization to Book Value Ratio VIRX (Viracta)|Market Capitalization to Book Value Ratio MOR|Market Cap to Net Assets Ratio nayabiosciences.com NAYA|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)